U.S. limits use of J&J’s COVID vaccine on blood clot risks

Author of the article: The U.S. health regulator said on Thursday it was limiting the use of Johnson & Johnson’s COVID-19 vaccine for adults due to the risk of a rare blood clotting syndrome, the latest setback to the shot that has been eclipsed by rivals. The J&J shot, which received U.S. clearance in February…
U.S. limits use of J&J’s COVID vaccine on blood clot risks

Author of the article:

The U.S. health regulator said on Thursday it was limiting the use of Johnson & Johnson’s COVID-19 vaccine for adults due to the risk of a rare blood clotting syndrome, the latest setback to the shot that has been eclipsed by rivals.

The J&J shot, which received U.S. clearance in February 2021 for adults, can be administered in cases where authorized or approved COVID-19 vaccines are not accessible or if an individual is less keen on using the other two shots, the Food and Drug Administration said.

J&J is one of the three vaccines in use in the United States. The other two are from Moderna and Pfizer .

The vaccine maker said it has updated the U.S. COVID-19 vaccine fact sheet to warn about the risk of thrombosis with thrombocytopenia syndrome (TTS), a rare but potentially life-threatening condition.

Use of the J&J shot has been weak in high-income countries, hurt by reports of rare, potentially deadly blood clots, production issues, including an accidental mix-up of ingredients by a contract manufacturer, and concerns about efficacy.

The drugmaker last month rescinded its forecast for COVID-19 vaccine sales, citing a glut of supply.

Cases of TTS, which involves blood clots accompanied by a low level of platelets, have previously been reported in recipients of the J&J vaccine.

The FDA in January amended the fact sheet for the J&J vaccine to include the risk of immune thrombocytopenia, months after the European Union’s drugs regulator took similar action.

The FDA on Thursday said the risk of TTS warranted limiting the use of the single-dose shot after it conducted investigation of reported cases.

The U.S. Centers for Disease Control and Prevention in December had recommended that Americans choose to receive mRNA shots from Pfizer and Moderna over J&J’s vaccine due to the rare cases of blood clotting.

Around 18.7 million Americans have received a J&J COVID-19 shot compared with 217.5 million people who received the Moderna vaccine and 340.6 million people who received Pfizer’s shot, according to CDC.

(Reporting by Amruta Khandekar; Additional reporting by Rhea Binoy; Editing by Anil D’Silva, Shailesh Kuber and Uttaresh.V)

Financial Post Top Stories

Sign up to receive the daily top stories from the Financial Post, a division of Postmedia Network Inc.

By clicking on the sign up button you consent to receive the above newsletter from Postmedia Network Inc. You may unsubscribe any time by clicking on the unsubscribe link at the bottom of our emails. Postmedia Network Inc. | 365 Bloor Street East, Toronto, Ontario, M4W 3L4 | 416-383-2300

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published.

Related Posts
Asian stocks, FX tumble as Russia attacks Ukraine
Read More

Asian stocks, FX tumble as Russia attacks Ukraine

Author of the article: Asian currencies and stocks were battered on Thursday with shares in Singapore and India losing about 3% as Russian attacks on Ukraine spoiled investors appetite for risk. Russian forces fired missiles at several Ukrainian cities and landed troops on its south coast on Thursday, officials and media said, after President Vladimir…
Bond Turbulence Far From Over as Inflation Fears Haunt Fed Path
Read More

Bond Turbulence Far From Over as Inflation Fears Haunt Fed Path

Author of the article: Bloomberg News Liz Capo McCormick and Michael MacKenzie (Bloomberg) — Federal Reserve Chairman Jerome Powell beat back the market’s most aggressive predictions for the path of interest rates Wednesday, setting off a dovish surge in stocks and bonds. But in pouring cold water on the prospect for a jumbo-sized 75 basis…
Shopify to lay off 10% of workforce
Read More

Shopify to lay off 10% of workforce

'Ultimately, placing this bet was my call to make and I got this wrong': Tobi Lütke Author of the article: Shopify's headquarters in Ottawa. Photo by David Kawai/Bloomberg Canadian tech giant Shopify Inc. laid off 10 per cent of its workforce Tuesday after what its chief executive Tobi Lütke called a failed bet that e-commerce…